SELLAS reaches 80th event in Phase 3 REGAL trial of GPS in acute myeloid leukemia
FROM THE WIRE · FINANCE.YAHOO.COM
SELLAS Life Sciences Group, Inc. - Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralReaching the event triggers the final analysis of a pivotal trial, with results expected this quarter.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The pre-specified 80th event was reached in the REGAL trial.
- 02Database lock, unblinding and statistical analysis will follow.
- 03The company will report topline primary endpoint results this quarter.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets